Biography for Nick Paul Taylor
Nick Taylor, UK Correspondent
Nick Taylor is a freelance journalist with more than six years' experience of reporting on the global biopharma industry. Since graduating with a biology degree from the University of York, Nick has written for numerous healthcare publications, including Nature BioPharma Dealmakers, Life Science Leader and Outsourcing-Pharma. You can contact him at firstname.lastname@example.org and follow him on Twitter at @NickPaulTaylor.
Articles by Nick Paul Taylor
J. Craig Venter's Human Longevity, Inc (HLI) has appointed a chief operating officer to manage its burgeoning genome sequencing operation. Mark Windham has taken up the position, jumping ship from drug-testing lab Millennium Health, where he also served as COO.
Biogen is working with Columbia University Medical Center to build a database of genes and clinical traits from 1,500 people with amyotrophic lateral sclerosis (ALS). The project, which is partly funded by cash raised in the Ice Bucket Challenge, is intended to help Biogen understand how genes contribute to different forms of ALS.
Google has just swept aside any lingering questions about how seriously it is taking its life sciences operation. Now, instead of operating as part of the experimental Google X, life sciences is to sit alongside the legacy internet search unit as one of a clutch of businesses operating under the Alphabet umbrella.
Boehringer Ingelheim has upgraded to the latest version of InnovoCommerce's innovoPOINT.
A pair of VC darlings have hooked up to speed the development of targeted cancer therapies. The deal sees Flatiron Health combine its oncology cloud system with blood test data from Guardant Health to give drug developers a platform on which they can identify molecular targets and support enrollment in clinical trials.
Intel has unveiled its pitch to become the organization that pulls cancer data out of silos. The semiconductor giant has spent the past two years working on the problem with Oregon Health & Science University, bringing it to the point at which it is ready to open up the platform to other organizations.
Having played a major role in making consumer genomics feasible, Illumina is now looking to shape how the nascent sector develops. The company has teamed up with big-name VCs to create Helix, a deep-pocketed startup that is one part massive next-generation sequencing operation, one part app store for genomics.
Billionaire entrepreneur Patrick Soon-Shiong has teamed up with a medical center and research institute to set up a precision cancer hub. The deal connects the Big Data and immuno-oncology companies in Soon-Shiong's burgeoning NantWorks conglomerate to an emerging center of genomic research and molecular medicine in Pennsylvania.
On August 3, 2011, Dendreon shocked the biotech world by posting weak sales and forecasts for its cancer vaccine Provenge. The numbers blindsided investors, triggering a 64% collapse in Dendreon's share price and spreading panic through the biotech market. But, if U.S. law enforcement has it right, the news came as no surprise to one trader: Vitaly Korchevsky.
Roche is using smartphones to gather data on participants in a Parkinson's disease clinical trial between site visits. The devices will enable both active and passive data collection, with patients being asked to complete daily tests and smartphone sensors gathering information as they go about their lives.